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Valproate and child-bearing potential: new regulations 
 
Each encounter between a patient and clinician is likely to include an explicit or implicit evaluation of 
benefit versus risk, and should always be an exercise in person-centered medicine. New stipulations 
from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human 
(CMDh), a regulatory body representing European Union member states, about the use of valproate 
in women of child-bearing potential1 bring these age-old considerations into sharp relief. There will 
be a change in the marketing authorisation: valproate will be contraindicated in pregnancy and 
women of child-bearing potential not using effective contraception. This requires all clinicians who 
see people with epilepsy to think carefully again, even before changes to UK use of valproate are 
enforced by changes in the licence from the UK Medicines and Healthcare products Regulatory 
Agency (MHRA). The many challenges are brought out in two accompanying articles in this issue2,3. 
Importantly, no one should stop valproate use abruptly because of this announcement. 
The background is well established, and largely derived from prospective registries4. Babies born to 
mothers who take valproate medicines during pregnancy have up to a 10% risk of birth defects, 
compared to 2–3% background risk5, and a variable, sometimes unknown, risk on polytherapy with 
other antiepileptic drugs6. Some of these malformations may necessitate early corrective surgery; 
some are inoperable. There is an average reduction in IQ estimated at 6–11 points7,8 and up to 30–
40% risk of developmental disability9-11. Compared to the general population, the risk of autism 
spectrum disorders is threefold, and that of attention-deficit hyperactivity disorder is fivefold12-14.  
These consequences may come with a lifetime burden of medical and social care for the family and 
the state. Whilst some structural abnormalities may be detectable on prenatal screening, the 
intellectual and behavioural outcomes cannot be predicted. Animal models suggest that some risks 
may be passed to unexposed generations epigenetically15: this work needs replication and there are 
no studies in humans. Whatever additional risks emerge, there are already significant known risks 
associated with the use of valproate in pregnancy.  We should not assume any disease specificity: 
any use of valproate for any condition should be considered to carry these risks.  
In response to the accumulated evidence on risks, the MHRA issued advice to prescribers in 2015 
(https://www.gov.uk/drug-safety-update/medicines-related-to-valproate-risk-of-abnormal-
pregnancy-outcomes) and again in 2016 (https://www.gov.uk/drug-safety-update/medicines-
related-to-valproate-risk-of-abnormal-pregnancy-outcomes). Materials to communicate the risks 
included a booklet for professionals, a consultation checklist, and a guide and card for patients.  
However, patient surveys suggested that the message had not got through: about 1 in 5 women of 
child-bearing potential remained unaware of the risks 
(https://www.epilepsysociety.org.uk/news/Women-not-aware-epilepsy-medicine-risk-pregnancy-
27-09-2017). Following a further review and public hearing in London by the European 
Pharmacovigilance Risk Assessment Committee (PRAC), further guidance was issued by the PRAC 
and subsequently now by CMDh. These measures will strengthen restrictions on valproate use and 
introduce new measures to require appropriate counselling and information for affected women. A 
mandatory pregnancy prevention programme will be introduced, supported by a revised toolkit, 
with signed acknowledgement required. Table 1 lists the main points in the regulations.  
There are important points to be brought out. The simplest option might be to avoid valproate 
completely in women of child-bearing potential. But, based on one of the few randomised controlled 
trials in epilepsy, valproate is the best drug for some types of epilepsy16. Valproate use has not been 
banned in girls and women of child-bearing potential. We must guard against inadvertently replacing 
the problems of teratogenicity and neurotoxicity with that of an increased risk of sudden 
unexpected death in epilepsy because of loss of seizure control. The new regulations note: “It is 
recognised that for some women with epilepsy it may not be possible to stop valproate and they 
may have to continue treatment (with appropriate specialist care) in pregnancy”.  
The responsibility is on prescribers to facilitate informed consultation with women for whom 
valproate is being considered. The continued use of valproate requires proper informed discussion. 
Valproate may be the only effective drug for some people and others will be faced by the choice 
between the known risks of valproate and unknown risks of newer antiepileptic drugs. The 
regulations state the need to assess: “for the potential of becoming pregnant, and involving the 
patient in evaluating her individual circumstances and supporting informed decision making.” For 
example, some women cannot have children for medical reasons, and this will apply to some with 
severe epilepsies for which valproate is a key element of treatment; some people choose not to 
have children. So the discussion between clinicians and women with epilepsy needs to be 
appropriate and individualised. Like all people with epilepsy, women of child-bearing potential 
taking valproate need at least annual review. These are important and sensible regulations, and it is 
vital that all prescribers, in primary and other care, and dispensers, are made aware and heed them. 
The particular concern about counselling women who may not have had a consultation with an 
epilepsy specialist for some time, particularly those who have well-controlled epilepsy, may have 
been started on valproate before puberty, and are seen only in primary care, will be covered by the 
new regulations.  
Valproate can be a good drug for seizure control, and for some is life-saving, but comes with 
significant risks. The new regulations aim to reduce the number of people of child-bearing potential 
taking valproate. The effects of changing patterns of prescribing and reduced use of valproate need 
monitoring. There will probably be a registry of women who remain on valproate: such monitoring 
should also be extended to women who have come off valproate, so that the full effects of the new 
regulations can be evaluated at individual and population-wide levels. There remain challenges and 
opportunities: responsibilities and resources will both need allocation. If patients are empowered to 
make their decisions, there are likely to be some women who, even after informed consultation, 
choose to carry a pregnancy whilst taking valproate. There may be dose-dependence for some 
consequences8, and if valproate is used, dose reduction to the smallest effective dose, in two or 
three divided doses, should be considered, along with 5mg folic acid daily8. Discussion with support 
groups may help, and alternative child-bearing options may be relevant. It would not be appropriate 
to admonish either prescribers who accommodate this option, or the women themselves, but this 
decision must be well-documented, and should be periodically revisited.  
There will never be a trial of valproate of pregnancy outcomes in women of child-bearing potential, 
so it is more important than ever that historical observational data are collected systematically and 
published. Fundamental research into the mechanisms of action and toxicity of valproate, and 
possible genetic or other biomarkers of toxicity is essential, because as far as we can tell from 
current data, some exposed children are not affected. But unless and until rational and effective 
selection of valproate as a credibly safe therapy for some individual women becomes a reality, we 
should follow the new regulations. These regulations aim to increase safety, and where their 
application may be complex, epilepsy specialists should be involved. We need to manage and 
minimise risk. 
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Table 1 
The main points of CMDh guidance on VPA use in women of childbearing potential, and the 
pregnancy prevention programme 
 In pregnancy - valproate must not be used. However, it is recognised that for 
some women with epilepsy it may not be possible to stop valproate and they may 
have to continue treatment (with appropriate specialist care) in pregnancy. 
 In female patients from the time they become able to have children – valproate 
must not be used unless the conditions of the new pregnancy prevention 
programme are met. 
 Outer packaging of all valproate medicines must include a visual warning about 
the risks in pregnancy. In addition to boxed text, this may include a 
symbol/pictogram, with the details to be adapted at national level. 
 A patient reminder card will also be attached to the outer package for 
pharmacists to discuss with the patient each time the medicine is dispensed. 
 Companies that market valproate should also provide updated educational 
materials in the form of guides for healthcare professionals and patients. 
The main points of the new valproate pregnancy prevention programme are: 
 Assessing patients for the potential of becoming pregnant, and involving the 
patient in evaluating her individual circumstances and supporting informed 
decision making 
 pregnancy tests before starting and during treatment as needed 
 counselling patients about the risks of valproate treatment 
 explaining the need for effective contraception throughout treatment 
 carrying out reviews of treatment by a specialist at least annually 
 introduction of a new risk acknowledgement form that patients and prescribers 
will go through at each such review to confirm that appropriate advice has been 
given and understood. 
 It is important that no woman should stop taking sodium valproate without first 
consulting her doctor. Sodium valproate is available in the UK under brand names such 
as Epilim, Epival, Episenta, Convulex and Orlept.  
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